Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation

Han W Tun, K. H. Wallace, S. F. Grinton, Andras Khoor, Charles Dwayne Burger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Idiopathic pneumonia syndrome (IPS) is a noninfectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (AHSCT), which usually develops within the first 100 days after transplantation. Donor T-cell-derived tumor necrosis factor-α (TNF-α) may play a crucial role in the pathogenesis of IPS, and inhibition of TNF-α has been used as a therapeutic option. We report two patients who had late-onset IPS about day 150 after nonmyeloablative AHSCT (NMA-AHSCT). They responded well to etanercept in combination with standard immunosuppressive drugs. Both patients had relapses and responded to retreatment with etanercept-based therapy. One patient was alive at 30 months after the initial diagnosis on long-term maintenance therapy with etanercept. The second patient was lost to follow-up at our institution but died 13 months after the onset of IPS. Our two cases showed that IPS could develop late after NMA-AHSCT and inhibition of TNF-α activity can be therapeutically effective.

Original languageEnglish (US)
Pages (from-to)4492-4496
Number of pages5
JournalTransplantation Proceedings
Volume37
Issue number10
DOIs
StatePublished - Dec 2005

Fingerprint

Hematopoietic Stem Cell Transplantation
Pneumonia
Tumor Necrosis Factor-alpha
Therapeutics
Retreatment
Lost to Follow-Up
Immunosuppressive Agents
Transplantation
Etanercept
Tissue Donors
T-Lymphocytes
Recurrence
Lung
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

@article{2005d303135249f9a53494b3c9e9c503,
title = "Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation",
abstract = "Idiopathic pneumonia syndrome (IPS) is a noninfectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (AHSCT), which usually develops within the first 100 days after transplantation. Donor T-cell-derived tumor necrosis factor-α (TNF-α) may play a crucial role in the pathogenesis of IPS, and inhibition of TNF-α has been used as a therapeutic option. We report two patients who had late-onset IPS about day 150 after nonmyeloablative AHSCT (NMA-AHSCT). They responded well to etanercept in combination with standard immunosuppressive drugs. Both patients had relapses and responded to retreatment with etanercept-based therapy. One patient was alive at 30 months after the initial diagnosis on long-term maintenance therapy with etanercept. The second patient was lost to follow-up at our institution but died 13 months after the onset of IPS. Our two cases showed that IPS could develop late after NMA-AHSCT and inhibition of TNF-α activity can be therapeutically effective.",
author = "Tun, {Han W} and Wallace, {K. H.} and Grinton, {S. F.} and Andras Khoor and Burger, {Charles Dwayne}",
year = "2005",
month = "12",
doi = "10.1016/j.transproceed.2005.10.101",
language = "English (US)",
volume = "37",
pages = "4492--4496",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation

AU - Tun, Han W

AU - Wallace, K. H.

AU - Grinton, S. F.

AU - Khoor, Andras

AU - Burger, Charles Dwayne

PY - 2005/12

Y1 - 2005/12

N2 - Idiopathic pneumonia syndrome (IPS) is a noninfectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (AHSCT), which usually develops within the first 100 days after transplantation. Donor T-cell-derived tumor necrosis factor-α (TNF-α) may play a crucial role in the pathogenesis of IPS, and inhibition of TNF-α has been used as a therapeutic option. We report two patients who had late-onset IPS about day 150 after nonmyeloablative AHSCT (NMA-AHSCT). They responded well to etanercept in combination with standard immunosuppressive drugs. Both patients had relapses and responded to retreatment with etanercept-based therapy. One patient was alive at 30 months after the initial diagnosis on long-term maintenance therapy with etanercept. The second patient was lost to follow-up at our institution but died 13 months after the onset of IPS. Our two cases showed that IPS could develop late after NMA-AHSCT and inhibition of TNF-α activity can be therapeutically effective.

AB - Idiopathic pneumonia syndrome (IPS) is a noninfectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (AHSCT), which usually develops within the first 100 days after transplantation. Donor T-cell-derived tumor necrosis factor-α (TNF-α) may play a crucial role in the pathogenesis of IPS, and inhibition of TNF-α has been used as a therapeutic option. We report two patients who had late-onset IPS about day 150 after nonmyeloablative AHSCT (NMA-AHSCT). They responded well to etanercept in combination with standard immunosuppressive drugs. Both patients had relapses and responded to retreatment with etanercept-based therapy. One patient was alive at 30 months after the initial diagnosis on long-term maintenance therapy with etanercept. The second patient was lost to follow-up at our institution but died 13 months after the onset of IPS. Our two cases showed that IPS could develop late after NMA-AHSCT and inhibition of TNF-α activity can be therapeutically effective.

UR - http://www.scopus.com/inward/record.url?scp=29544448086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29544448086&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.10.101

DO - 10.1016/j.transproceed.2005.10.101

M3 - Article

C2 - 16387152

AN - SCOPUS:29544448086

VL - 37

SP - 4492

EP - 4496

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -